AB023. Evaluation the outcome of β-thalassemia intermedia patients on hydroxyurea combined with erythropoietin at National Children’s Hospital

摘要

BackgroundInherited hemoglobin disorders primarily exist in the low- or middle-income countries of the tropical belt stretching from Southeast Asia like Vietnam. β-thalassemia intermedia is caused by one of the more severe combined with a milder thalassemic gene. Children with thalassemia intermedia start to develop symptoms later in life than those with thalassemia major, usually becoming pale and developing symptoms around 2 years of age. Although β-thalassemia intermedia is in non-transfusion dependent, but some patients may require more frequent transfusions because of poor growth and development. The aim of this study was to evaluate the effective treatment of hydroxyurea (HU) and erythropoietin in β-thalassemia intermedia patients.